Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Heavy Metal Poisoning - Pipeline Review, H1 2017Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies.
By: Ethocle Reports Published On: 31-Mar-2017 | Pages: 41 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning – Pipeline Review, H1 2017, provides an overview of the Heavy Metal Poisoning (Toxicology) Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy. Click here (http://www.ethoclereports.com/ Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology) The Heavy Metal Poisoning (Toxicology) The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Get Free Sample Report (http://www.ethoclereports.com/ Click here (http://www.ethoclereports.com/ Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology) - The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) - The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology) - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Heavy Metal Poisoning – Overview Heavy Metal Poisoning – Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/ Products under Development by Companies Products under Development by Universities/ Heavy Metal Poisoning – Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Heavy Metal Poisoning – Companies Involved in Therapeutics Development Alnylam Pharmaceuticals Inc La Jolla Pharmaceutical Company Medesis Pharma SA Novartis AG PDX Pharmaceuticals LLC Heavy Metal Poisoning – Drug Profiles ALN-TMP – Drug Profile Product Description Mechanism Of Action R&D Progress deferasirox – Drug Profile Product Description Mechanism Of Action R&D Progress deferoxamine mesylate – Drug Profile Product Description Mechanism Of Action R&D Progress emeramide – Drug Profile Product Description Mechanism Of Action R&D Progress LJPC-401 – Drug Profile Product Description Mechanism Of Action R&D Progress NU-01 – Drug Profile Product Description Mechanism Of Action R&D Progress NU-02 – Drug Profile Product Description Mechanism Of Action R&D Progress NU-03 – Drug Profile Product Description Mechanism Of Action R&D Progress PDX-003 – Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Heavy Metal Poisoning – Drug Profile Product Description Mechanism Of Action R&D Progress Heavy Metal Poisoning – Dormant Projects Heavy Metal Poisoning – Discontinued Products Heavy Metal Poisoning – Product Development Milestones End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|